bit.bio, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report, reaffirming its commitment to measurable progress across ethics, sustainability, and operational impact.
The report provides evidence-based metrics aligned with the UN Sustainable Development Goals (SDGs), highlighting year-over-year improvements.
It demonstrates how sustainability is integrated across all aspects of bit.bio’s operations, from its scientific platform, laboratory operations and corporate governance, while reinforcing the company’s commitment in transparency and accountability to customers, partners, investors and employees.
This report builds on bit.bio’s inaugural 2024 Sustainability Report, which established bit.bio’s baseline commitments across three primary SDGs, including Good Health & Well-Being (SDG 3), Industry, Innovation & Infrastructure (SDG 9), and Life on Land (SDG 15) alongside seven secondary SDGs guiding daily operations.
The 2025 report demonstrates how those commitments have translated into measurable progress and operational change over the past year.
The report is published at a time when governments and regulators in the UK and US are taking concrete steps to reduce reliance on animal testing and accelerate the use of New Approach Methodologies (NAMs).
New UK policy commitments to phase out specific animal tests, together with the US Food and Drug Administration’s roadmap to replace parts of preclinical safety testing with NAMs signal a global shift towards models based on human cells, advanced in vitro assays and in silico tools. bit.bio’s ioCells portfolio of human iPSC-derived products and its focus on making these tools more affordable and accessible is directly aligned with this policy direction.
